Medipattern Closes First Tranche of Private Placement Financing

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Attention: Business/Financial Editors 

The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), is pleased to
announce today that it has closed on the first tranche of a brokered private
placement financing (the "Offering") with Industrial Alliance Securities Inc. as
the lead agent, for aggregate gross proceeds of $1,792,500. Medipattern issued
7,170,000 units (each a "Unit") at a price of $0.25 per Unit. 


Each Unit consists of one common share and one-half of one common share purchase
warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder
thereof to purchase one common share at an exercise price of $0.30 per common
share at any time on or before the date that is 60 months following the closing
of the Offering, provided that if, at any time after the date which is four
months and one day following the closing date of the Offering, the volume
weighted average closing price of the common shares of Medipattern on the
principal market on which such shares trade is equal to or exceeds $0.60 for 20
consecutive trading days, Medipattern may accelerate the expiry date of the
Warrants, in which event the Warrants will expire upon the date (the
"Accelerated Expiry Date") which is 20 days following the dissemination of a
press release by Medipattern announcing the Accelerated Expiry Date.


In connection with the Offering, Medipattern paid an aggregate amount of $71,700
in cash agency fees and also issued an aggregate of 573,600 agent warrants (the
"Agent Warrants"). Each Agent Warrant entitles the holder thereof to acquire one
common share of Medipattern at a price of $0.25 per Agent Warrant at any time on
or before the date that is 24 months following the closing of the Offering. 


All securities issued pursuant to the Offering are subject to a four month and
one day hold period from the closing of the Offering as required by applicable
securities legislation and the rules of the TSX Venture Exchange.


Medipattern plans to use the proceeds from the proposed private placement
financing to provide working capital for its current business, including its
focus on commercializing Visualize:Vascular(TM), and upon closing of the
transaction with MYTRAK(R) Health System Inc. announced on May 28, 2012, to
expand the business unit of MyTrak Mobile Health Solutions.


The securities offered in the placement have not been and will not be registered
under the United States Securities Act of 1933, as amended, (the "U.S.
Securities Act"), and may not be offered or sold within the United States or to,
or for the account or benefit of U.S. persons except in certain transactions
exempt from the registration requirements of the U.S. Securities Act.


About The Medipattern Corporation: 

Medipattern(R) is a pioneer in the development of imaging software solutions
that help medical practitioners to better understand lesions and critical
anatomy. Medipattern uses its Cadenza(TM) technology to process images, finding
the salient region of interest and presenting them in 2D and 3D formats that
enhance the reader's perception. For more information, please visit the
Company's website: www.medipattern.com.


Medipattern(R) is a registered mark of The Medipattern Corporation. Cadenza(TM)
and Visualize:Vascular(TM) are trademarks of the Medipattern Corporation. 


Forward-looking statements 

This document contains forward-looking statements relating to Medipattern's
performance, operations, or business environment. These statements are based on
what we believe are reasonable assumptions given currently available information
and our understanding of Medipattern's current activities. We have tried,
whenever possible, to identify these forward-looking statements using words such
as "anticipates," "believes," "estimates," "expects," "plans," "intends,"
"potential", and similar expressions. Forward-looking statements are not
guarantees of future performance and involve risks and uncertainties that are
difficult to predict or control. A number of factors could cause actual outcomes
and results to differ materially from those expressed in forward-looking
statements. These factors include but are not limited to those set forth in the
Company's corporate filings, (posted at www.sedar.com). In addition, these
forward-looking statements relate to the date on which they are made. The
Company disclaims any intention or obligation to update or revise any
forward-looking statements for any reason. Readers should not rely on
forward-looking statements.